Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

FDA Flags Moderna Flu Vaccine Evidence; Triggering Market and Approval Shock

The U.S. Food and Drug Administration (U.S. Food and Drug Administration) staff have raised concerns about the evidence supporting Moderna’s (Moderna) experimental flu vaccine mFlusiva ahead of a key advisory panel meeting in Washington. Regulators questioned the strength and completeness
  • News
FDA Flags Moderna Flu Vaccine Evidence; Triggering Market and Approval Shock

Regulations for Pharmaceutical Companies in 2026: FDA, EMA, GMP Rules, and Quality System Controls

This article explores evolving pharmaceutical regulatory compliance and GMP requirements shaping global manufacturing. It explains FDA and EMA inspection expectations, data integrity standards, and quality risk management frameworks that define how pharmaceutical companies maintain inspection readiness and regulatory alignment.
  • Blog, Quality Management System
Pharmacist in GMP laboratory analyzing digital compliance systems and regulatory framework linked to FDA GMP inspection findings and EMA regulatory requirements in pharmaceutical quality compliance

Neumora MDD Phase III Failure; KOASTAL Trials Collapse Forces Program Shutdown

Neumora Therapeutics has reported three consecutive Phase III failures for its major depressive disorder candidate navacaprant after KOASTAL-2 and KOASTAL-3 failed to meet primary and key secondary endpoints. The company confirmed it will discontinue development of the asset and reduce
  • News
Neumora MDD Phase III Failure; KOASTAL Trials Collapse Forces Program Shutdown

FDA Flags Weight Loss Endpoints as Inadequate; Obesity Trials Under Regulatory Pressure

Regulators and industry stakeholders are reassessing whether body weight alone is a sufficient endpoint for obesity therapies. In a recent Boehringer Ingelheim discussion, Brian Hilberdink highlighted a shift toward metabolic health as a more meaningful indicator of clinical benefit. The
  • News
FDA Flags Weight Loss Endpoints as Inadequate; Obesity Trials Under Regulatory Pressure

Batch surveillance in pharma in 2026: GMP Monitoring, Quality Risks, and Inspection Readiness

This article explains how batch surveillance system in pharma improves GMP oversight through real time batch monitoring GMP, stronger data integrity monitoring in pharma, and enhanced QA real time oversight pharma, enabling faster deviation detection and better inspection readiness across
  • Blog, Quality Management System
GMP surveillance workflow illustrating batch surveillance system in pharma, data integrity monitoring in pharma, and deviation detection in pharmaceutical manufacturing through QA real time oversight pharma and manufacturing batch quality control processes.

Rare Disease Diagnoses Inside Biotech Leaders at Sarepta; Drug Pipelines Face Emotional Collapse

In a feature published on June 16, 2026, BioSpace highlighted six real-world cases where drug development shifted from corporate strategy to deeply personal missions. The report shows how rare disease diagnoses within families of biotech leaders influenced company formation, clinical
  • News
Rare Disease Diagnoses Inside Biotech Leaders at Sarepta; Drug Pipelines Face Emotional Collapse

Simcere–Stanford IPF Deal; Unlocks High-Stakes Fibrosis Drug Race

Simcere Pharmaceutical Group has launched a research collaboration with Stanford Medicine to develop potential first-in-class therapies for idiopathic pulmonary fibrosis (IPF), a progressive and life-threatening lung disease. Under this agreement announced on June 15, 2026, Simcere Pharmaceutical Group funds early
  • News
Simcere–Stanford IPF Deal; Unlocks High-Stakes Fibrosis Drug Race

Batch Record in Pharmaceutical Industry in 2026: GMP Documentation, QA Review, and Batch Release Control

This article explains batch manufacturing record systems in the pharmaceutical industry, focusing on GMP documentation requirements, QA review processes, and pharmaceutical batch release process. It also highlights FDA GMP inspection findings, ALCOA+ data integrity, and CFR Part 11 compliance controls.
  • Blog, Quality Management System
Batch production record workflow in pharmaceutical manufacturing illustrating GMP documentation requirements, QA batch record review process, deviation control, and electronic batch record system aligned with CFR Part 11 electronic records and data integrity ALCOA plus compliance.